Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingJun 7, 2023Pilocarpine Hydrochloride Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0861-2023Class IIOngoingJun 7, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0860-2023Class IIOngoingJun 7, 2023Midazolam InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0859-2023Class IIOngoingJun 7, 2023Calcitriol Injection 2 mcg/mLCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0858-2023Class IIOngoingJun 7, 2023Amantadine Hydrochloride Oral Solution USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0857-2023Class IIOngoingJun 7, 2023XOPENEXCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0856-2023Class IIOngoingJun 7, 2023Vitamin D Supplement DropsCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0855-2023Class IIOngoingJun 7, 2023Valproic Acid Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0854-2023Class IIOngoingJun 7, 2023Tropicamide Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0853-2023Class IIOngoingJun 7, 2023Trihexyphenidyl Hydrochloride Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0852-2023Class IIOngoingJun 7, 2023Tobramycin Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0851-2023Class IIOngoingJun 7, 2023Tobramycin Inhalation Solution USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0850-2023Class IIOngoingJun 7, 2023Timolol Maleate Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0849-2023Class IIOngoingJun 7, 2023Sulfamethoxazole & Trimethoprim Oral Suspension USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0848-2023Class IIOngoingJun 7, 2023SufentaCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0847-2023Class IIOngoingJun 7, 2023Sodium DIURILCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0846-2023Class IIOngoingJun 7, 2023Sodium Chloride Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0845-2023Class IIOngoingJun 7, 2023Sodium Chloride Ophthalmic OintmentCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0844-2023Class IIOngoingJun 7, 2023Fentanyl Citrate InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0843-2023Class IIOngoingJun 7, 2023Ropivacaine Hydrochloride Injection USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0842-2023Class IIOngoingJun 7, 2023Rifampin Capsules USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0841-2023Class IIOngoingJun 7, 2023Rifampin Capsules USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0840-2023Class IIOngoingJun 7, 2023Proparacaine HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0839-2023Class IIOngoingJun 7, 2023Promethazine HCl Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0838-2023Class IIOngoingJun 7, 2023Promethazine HCl & Codeine Phosphate Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0837-2023Class IIOngoingJun 7, 2023Prednisolone Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0836-2023Class IIOngoingJun 7, 2023Pilocarpine Hydrochloride Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0835-2023Class IIOngoingJun 7, 2023Oxcarbazepine Oral SuspensionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0834-2023Class IIOngoingJun 7, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0833-2023Class IIOngoingJun 7, 2023Olopatadine HCl Nasal SprayCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0832-2023Class IIOngoingJun 7, 2023Neomycin & Polymyxin B SulfatesCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0831-2023Class IIOngoingJun 7, 2023Naloxone InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0830-2023Class IIOngoingJun 7, 2023Moxifloxacin HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0829-2023Class IIOngoingJun 7, 2023Midazolam InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0828-2023Class IIOngoingJun 7, 2023Megestrol Acetate Oral SuspensionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0827-2023Class IIOngoingJun 7, 2023Lorazepam Oral ConcentrateCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0826-2023Class IIOngoingJun 7, 2023Lorazepam InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0825-2023Class IIOngoingJun 7, 2023Lidocaine Hydrochloride Oral Topical SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0824-2023Class IIOngoingJun 7, 2023Lidocaine HCl Jelly USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0823-2023Class IIOngoingJun 7, 2023Lidocaine Ointment USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0822-2023

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.